Additional Information
Book Details
Abstract
This issue of Hematology/Oncology Clinics of North America, devoted to Multiple Myeloma, is edited by Dr. Kenneth C. Anderson. Articles in this issue include: Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma; Diagnosis and Risk Stratification in Myeloma; Treatment of Newly Diagnosed Transplant Eligible Patients; Treatment of Newly Diagnosed Transplant Ineligible Patients; Treatment of Relapsed/Refractory Myeloma; Maintenance Therapy; Novel Targeted Therapies; Novel Immune-based Therapies; Allotransplantation in Myeloma; and Waldenstrom’s Macroglobulinemia.
Table of Contents
| Section Title | Page | Action | Price |
|---|---|---|---|
| Front Cover | Cover | ||
| Multiple Myeloma\r | i | ||
| Copyright\r | ii | ||
| Contributors | iii | ||
| Contents | vii | ||
| Hematology/Oncology Clinics Of North America\r | x | ||
| Preface\r | xi | ||
| Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma | 775 | ||
| Key points | 775 | ||
| Introduction | 775 | ||
| Recognition of monoclonal gammopathies | 776 | ||
| Monoclonal gammopathy of undetermined significance | 776 | ||
| Definition | 776 | ||
| Prevalence | 776 | ||
| Light Chain MGUS | 778 | ||
| Etiology | 778 | ||
| Long-Term Outcome of MGUS | 778 | ||
| Risk Factors for Progression | 779 | ||
| Size and type of serum M protein | 779 | ||
| Bone marrow plasma cells | 779 | ||
| Serum FLC ratio | 780 | ||
| Aberrant plasma cells | 781 | ||
| Risk Stratification | 781 | ||
| Differential Diagnosis | 781 | ||
| Secondary MGUS | 781 | ||
| Monoclonal gammopathy of renal significance | 781 | ||
| Idiopathic Bence Jones proteinuria | 781 | ||
| Management of MGUS | 782 | ||
| Low-Risk MGUS | 782 | ||
| Intermediate and High-Risk MGUS | 782 | ||
| Second Malignancies | 782 | ||
| Smoldering (asymptomatic) multiple myeloma | 782 | ||
| Definition | 782 | ||
| Risk Factors Predicting Disease Progression | 783 | ||
| Size of M protein and extent of marrow involvement | 783 | ||
| Serum FLC ratio | 783 | ||
| Circulating plasma cells | 784 | ||
| Immunophenotype and immunoparesis | 784 | ||
| Imaging | 784 | ||
| Cytogenetic abnormalities | 784 | ||
| Risk-Stratification of SMM | 784 | ||
| Management of SMM | 785 | ||
| Summary | 786 | ||
| References | 786 | ||
| Diagnosis and Risk Stratification in Multiple Myeloma | 791 | ||
| Key points | 791 | ||
| Clinical presentation | 791 | ||
| Differential diagnosis | 792 | ||
| Diagnostic workup of MM | 792 | ||
| Prognostic factors | 792 | ||
| Disease characteristics | 795 | ||
| Conventional Cytogenetics | 795 | ||
| FISH | 795 | ||
| Multiple Adverse Cytogenetic Abnormalities | 796 | ||
| Good Combined with Adverse Cytogenetic Abnormalities | 796 | ||
| Gene Expression Profiling | 797 | ||
| Plasma Cell Proliferation | 797 | ||
| Lactate Dehydrogenase | 798 | ||
| M Protein Isotype | 798 | ||
| EM Myeloma and Primary Plasma Cell Leukemia | 798 | ||
| Imaging Characteristics | 799 | ||
| Other Factors | 799 | ||
| Patient characteristics | 799 | ||
| Geriatric Assessment | 799 | ||
| Sociodemographic Factors | 799 | ||
| Renal Function | 800 | ||
| Therapy-Related Characteristics | 800 | ||
| Importance of Complete Response | 800 | ||
| Immunophenotypic and Molecular CR | 801 | ||
| PET/CT and MRI | 801 | ||
| PET/CT | 801 | ||
| MRI | 802 | ||
| Models combining patient and disease characteristics | 802 | ||
| Durie-Salmon Classification | 802 | ||
| ISS | 802 | ||
| Mayo Stratification of Myeloma and Risk-Adapted Therapy | 803 | ||
| ISS and FISH | 803 | ||
| ISS, FISH, and failure to achieve CR after induction therapy | 804 | ||
| ISS and LDH | 804 | ||
| ISS, LDH, and FISH | 804 | ||
| Concluding remarks and future perspectives | 804 | ||
| References | 806 | ||
| Treatment of Transplant-Eligible Patients with Multiple Myeloma in 2014 | 815 | ||
| Key points | 815 | ||
| Introduction | 815 | ||
| Defining an optimal induction regimen | 816 | ||
| Role of HDT and SCT | 817 | ||
| Preventing relapse | 819 | ||
| Summary and future directions | 821 | ||
| References | 822 | ||
| Frontline Therapy for Patients with Multiple Myeloma not Eligible for Stem Cell Transplantation | 829 | ||
| Key points | 829 | ||
| Introduction | 829 | ||
| Thalidomide-based regimens | 830 | ||
| Thalidomide-Dexamethasone | 830 | ||
| Melphalan-Prednisone-Thalidomide | 830 | ||
| Cyclophosphamide-Thalidomide-Dexamethasone | 830 | ||
| Bortezomib-based regimens | 831 | ||
| Bortezomib-Melphalan-Prednisone | 831 | ||
| VMP Modified | 831 | ||
| Bortezomib-Cyclophosphamide-Dexamethasone, Bortezomib-Lenalidomide-Dexamethasone | 832 | ||
| Lenalidomide-based regimens | 832 | ||
| Lenalidomide–Low-dose Dexamethasone | 832 | ||
| Melphalan-Prednisone-Lenalidomide | 833 | ||
| Unfit patients | 833 | ||
| Maintenance therapy | 834 | ||
| Future directions | 835 | ||
| References | 835 | ||
| Maintenance Therapy for Multiple Myeloma | 839 | ||
| Key points | 839 | ||
| Introduction | 839 | ||
| Maintenance approaches for patients ineligible for transplantation | 840 | ||
| Thalidomide | 840 | ||
| Lenalidomide | 841 | ||
| Bortezomib | 844 | ||
| Maintenance approaches for patients eligible for transplantation | 845 | ||
| Thalidomide | 845 | ||
| Zoledronate | 846 | ||
| Lenalidomide | 847 | ||
| Bortezomib | 852 | ||
| Summary | 853 | ||
| Acknowledgments | 854 | ||
| References | 854 | ||
| Relapsed and Refractory Multiple Myeloma | 861 | ||
| Key points | 861 | ||
| Introduction | 861 | ||
| The achievement of complete remission | 862 | ||
| Prognostic factors | 863 | ||
| Impact of Cytogenetic Abnormalities | 863 | ||
| Impact of Previous Therapy, Retreatment, and Sequence of Drugs | 864 | ||
| Current treatment options for RRMM | 866 | ||
| Thalidomide | 866 | ||
| Bortezomib | 866 | ||
| Lenalidomide | 868 | ||
| Carfilzomib | 869 | ||
| Pomalidomide | 874 | ||
| Combinations of Novel Agents | 878 | ||
| The future of therapy: emerging agents and novel treatment strategies | 878 | ||
| Histone Deacetylase Inhibitors | 879 | ||
| Monoclonal Antibodies | 879 | ||
| Kinesin Spindle Protein Inhibitors | 881 | ||
| Summary | 882 | ||
| References | 882 | ||
| Allogeneic Stem Cell Transplantation for Multiple Myeloma | 891 | ||
| Key points | 891 | ||
| Introduction | 891 | ||
| History | 892 | ||
| Reduced-intensity conditioning regimens | 893 | ||
| GVHD and relapse | 893 | ||
| HI-risk myeloma | 895 | ||
| Prospective comparisons of tandem ASCT versus ASCT-AlloSCT | 895 | ||
| Recent reports | 897 | ||
| Summary and future studies | 898 | ||
| References | 899 | ||
| Novel Targeted Agents in the Treatment of Multiple Myeloma | 903 | ||
| Key points | 903 | ||
| Introduction | 903 | ||
| Second-generation proteosome inhibitors | 904 | ||
| Ixazomib (MLN9708) | 904 | ||
| Oprozomib (ONX 0912) | 906 | ||
| NPI-0052 (Marizomib) | 906 | ||
| Cell signaling agents | 906 | ||
| Histone Deacetylases Inhibitors | 906 | ||
| Panobinostat | 907 | ||
| Vorinostat | 908 | ||
| ACY-1215 (Rocilinostat) | 908 | ||
| Heat-Shock Protein 90 Inhibitors | 909 | ||
| Phosphoinosiide 3-kinase/Akt/Mammalian Target of Rapamycin Pathway Inhibitors | 910 | ||
| BET Bromodomain Inhibitors | 911 | ||
| Deubiquitinating Enzyme Inhibitors | 911 | ||
| Wnt, Hedgehog, Notch Inhibitors | 911 | ||
| Wnt | 911 | ||
| Notch | 911 | ||
| Hedgehog | 912 | ||
| Kinesin Spindle Protein Inhibitors | 912 | ||
| Chromosome Region Maintenance 1 | 912 | ||
| Targeting the bone marrow microenvironment | 913 | ||
| Hypoxia | 913 | ||
| Angiogenesis | 913 | ||
| CXCR4 | 913 | ||
| Cell cycle inhibitors | 913 | ||
| Aurora Kinase Inhibitors | 913 | ||
| Cyclin-Dependent Kinase Inhibitors | 914 | ||
| Monoclonal antibodies | 914 | ||
| Anti-CS1 (Elotuzumab) | 914 | ||
| Anti-CD38 | 916 | ||
| Daratumumab | 916 | ||
| SAR650984 | 916 | ||
| Anti–IL-6 (Siltuximab) | 917 | ||
| Novel cytotoxics | 917 | ||
| Melflufen | 917 | ||
| Summary | 918 | ||
| References | 918 | ||
| Immunotherapy Strategies in Multiple Myeloma | 927 | ||
| Key points | 927 | ||
| Passive-specific immunotherapy | 928 | ||
| Active-specific immunotherapy | 928 | ||
| Future directions | 935 | ||
| References | 935 | ||
| Waldenström Macroglobulinemia | 945 | ||
| Key points | 945 | ||
| Introduction | 945 | ||
| Epidemiology | 945 | ||
| Biology | 946 | ||
| Cytogenetics | 946 | ||
| Mutation in MYD88 | 946 | ||
| CXCR4 WHIM Mutations | 948 | ||
| Clinical features | 948 | ||
| Morbidity mediated by the effects of IgM | 948 | ||
| Hyperviscosity Syndrome | 948 | ||
| Cryoglobulinemia | 949 | ||
| IgM-Related Neuropathy | 949 | ||
| Cold Agglutinin Hemolytic Anemia | 950 | ||
| Amyloidosis and Other Deposition Disease | 950 | ||
| Laboratory investigations and findings | 951 | ||
| Hematological Abnormalities | 951 | ||
| Biochemical Investigations | 951 | ||
| Serum Viscosity | 951 | ||
| Bone Marrow Findings | 951 | ||
| Prognosis and risk stratification | 952 | ||
| Treatment of Waldenström macroglobulinemia | 953 | ||
| Treatment Indications | 953 | ||
| Treatment Options | 953 | ||
| Monoclonal antibodies | 954 | ||
| Alkylating agents | 954 | ||
| Nucleoside analogs | 956 | ||
| Proteasome inhibitors | 958 | ||
| Immunomodulatory agents | 959 | ||
| Everolimus | 960 | ||
| Ibrutinib | 960 | ||
| Maintenance therapy | 960 | ||
| High-dose therapy and stem cell transplantation | 961 | ||
| Response criteria in Waldenström macroglobulinemia | 961 | ||
| Summary | 962 | ||
| References | 963 | ||
| Index | 971 |